Abstract
Background : Definitive chemoradiotherapy (dCRT) plays an important role in the treatment of esophageal cancer, however, many types of adverse events are caused by dCRT. Hematotoxicity is one of the most frequent and serious one. When we choose the method of treatment, how to predict the hematotoxicity becomes an issue.
Method : Twenty-five patients treated with dCRT (JCOG9906 regimen ; 5-FU/CDDP and radiation 60Gy) for thoracic esophageal cancer in our hospital from 2004 to 2009 were enrolled in this study to analyze CCL2/MCP-1-2518 A>G and IL-6-634 C>G genetic polymorphisms from DNA extracted from their peripheral blood by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). We investigated the hemototoxicity (decrease in white blood cell count and decrease in platelet count) from the initiation of dCRT until 3 weeks after the completion and retrospectively analyzed the relationships between the hematotoxicity and genetic polymorphisms.
Results : White blood cell decrease (CTCAE Grade 3 or higher) occurred significantly more in patients with the CCL2/MCP-1-2518 G/G genotype than in those with the A/G+A/A genotype. Platelet decrease (CTCAE Grade 2 or higher) occurred significantly more in patients with the IL-6-634 C/G genotype than those with the C/C genotype.
Conclusions : The hematotoxicity of dCRT for thoracic esophageal cancer can be predicted by the CCL2/MCP-1-2518 A>G genetic polymorphism and IL-6-634 C>G genetic polymorphism, which are related to the hematogenous functions.
